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Herpes B virus (B virus [BV]) is a macaque herpesvirus that is occasionally transmitted to humans where
it can cause rapidly ascending encephalitis that is often fatal. To understand the low susceptibility of BV to the
acyclonucleosides, we have cloned, expressed, and characterized the BV thymidine kinase (TK), an enzyme that
is expected to “activate” nucleoside analogs. This enzyme is similar in sequence and properties to the TK of
herpes simplex virus (HSV), i.e., it has a broad substrate range and low enantioselectivity and is sensitive to
inhibitors of HSV TKs. The BV enzyme phosphorylates some modified nucleosides and acyclonucleosides and
L enantiomers of thymidine and related antiherpetic analogs. However, the potent anti-HSV drugs acyclovir
(ACV), ganciclovir (GCV), and 5-bromovinyldeoxyuridine were poorly or not phosphorylated by the BV enzyme
under the experimental conditions. The antiviral activities of a number of marketed antiherpes drugs and
experimental compounds were compared against BV strains and, for comparison, HSV type 1 (HSV-1) in Vero
cell cultures. For most compounds tested, BV was found to be about as sensitive as HSV-1 was. However, BV
was less sensitive to ACV and GCV than HSV-1 was. The abilities of thymidine analogs and acyclonucleosides
to inhibit replication of BV in Vero cell culture were not always proportional to their substrate properties for
BV TK. Our studies characterize BV TK for the first time and suggest new lead compounds, e.g., 5-ethyl-
deoxyuridine and pencyclovir, which may be superior to ACV or GCV as treatment for this emerging infectious
disease.
Herpes B virus (Cercopithecine herpesvirus 1) (BV) is an
alphaherpesvirus that naturally infects members of the genus
Macaca. In macaques, infection with BV is usually asymptom-
atic but can present as lesions on the face, in the mouth, or in
the genital region. The lesions heal spontaneously but may
appear again sporadically in the same way that oral and genital
herpes simplex do in humans. However, when transmitted to
humans, BV causes an acute ascending encephalitis that is
usually fatal if not treated immediately (19). Transmission
of BV to humans usually occurs through monkey bites or
contact with infected monkey tissues or fluids. BV has been
classified as a select agent by the U.S. Public Health Service
(42CFR73.3).
Although BV is highly lethal in humans, the infrequency of
human BV infections has not encouraged development of
drugs specifically targeted to this virus. However, the extreme
severity of BV infections makes this virus the primary zoonotic
concern for persons working with macaques. Acyclovir (ACV),
a drug widely used to treat herpes simplex virus (HSV) infec-
tions, is currently recommended for treatment of BV infections
as well (3). However, BV is about 10 times less susceptible than
HSV is to ACV and the related drug ganciclovir (GCV) (1, 3).
No studies have examined the comparative sensitivity of BV to
other antiherpes drugs, nor has the molecular basis of the
lower susceptibility of BV to ACV or GCV been studied. With
the increasing use of rhesus monkeys in biomedical research
and the accompanying potential for more human BV infec-
tions, identification of antiviral drugs that are more effective in
controlling BV infections is warranted.
Most of the antiherpes drugs used clinically or experimen-
tally against human herpesviruses (HSV type 1 [HSV-1],
HSV-2, varicella-zoster virus, and cytomegalovirus) are nucle-
oside analogs that are activated in infected cells by virus-en-
coded thymidine kinase (TK). Ultimately, the analogs are me-
tabolized to the triphosphate form that is incorporated into the
replicating viral DNA by the viral DNA polymerase, causing
chain termination (reviewed in reference 20). Interestingly,
HSV TKs are not stereoselective, being able to phosphorylate
both enantiomers of thymidine (TdR) and other TdR analogs.
Some inhibitors of the HSV TKs have been shown to block
reactivation of latent HSV in animal models (21). Identifica-
tion of drugs having a similar activity against BV would be of
great value in treating human BV infections. This work was
undertaken to study the properties of the key BV enzymes
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involved in DNA replication of the virus and to use their
unique properties to find or design potential drugs to treat BV
infections in humans. In this paper we focus on BV TK and
report its relevance to the sensitivity of BV to various antiher-
pes drugs.
MATERIALS AND METHODS
Viruses and cells. The standard E2490 laboratory strain of BV was used for
initial studies, and three field isolates of BV (24105, 32425, and E90-136) were
also used (15). The F strain of HSV-1 was used for comparison studies. All virus
propagation and experimental assays were performed in Vero cells, and all work
with infectious BV was conducted under biosafety level 3. Cells were grown in
Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) and maintained after experimental infection in DMEM
containing 2% FBS.
Chemicals. Analytical-grade reagents were used exclusively. Bacterial medium
components were from Difco, and Ni-nitrilotriacetic acid (Ni-NTA) Superflow
resin was from QIAGEN. Restriction and modification enzymes were from
Promega, Sigma, or Roche. Isopropylthio--D-galactoside (IPTG) was from
Sigma, and [3H]thymidine, 20 Ci/mmol, was from New England Nuclear. The
acyclonucleosides ACV, GCV, and pencyclovir (PCV), the thymidine analogs
5-iodo-2-deoxyuridine (IUdR), 5-trifluoromethyl-2-deoxyuridine (TFT), and
E-(5-bromovinyl)-2-deoxyuridine (BVdU), and foscarnet (PFA) were available
commercially. Cidofovir (CFV) was a gift from Gilead Sciences Inc. Authors
contributed the following experimental compounds: 9-(4-hydroxybutyl)guanine
(HBG), 9-(4-hydroxybutyl)-N2-phenylguanine (HBPG), and related TK inhibi-
tors (G. E. Wright) (13, 22); 5-ethyl-2-deoxyuridine (Et-dU,  and  anomers)
and -5-propyl-2-deoxyuridine (Pr-dU) (D. Shugar) (5, 18); L-thymidine (L-
TdR), L-5-iodo-2-deoxyuridine (L-IUdR), and L-E-(5-bromovinyl)-2-deoxyuri-
dine) (L-BVdU) (F. Focher) (16, 17). Structures of compounds used in this work
are shown in Fig. 1.
Construction of recombinant bacterial expression vector for BV TK. The TK
gene of BV strain E2490 (GenBank accession number AB096160) was inserted
in pTopo and amplified by PCR by using the following primers: 5-GAACATG
CTCGAGCACGCCGGCCATCAGGATGC-3 (primer 1, sense) and 5-ACG
TCTGTTCGAACCATCTTTATTGCGCC-3 (primer 2, antisense). The ampli-
fied product was digested with XhoI and Csp45I (present in the primers) and
inserted into the multiple cloning site of pTrcHisA (Invitrogen), previously
digested with the same restriction enzymes, to give the recombinant bacterial
expression vector pHis-BV-TK, which contains the complete BV TK sequence
with an N-terminal His6 tag, resulting in a protein of the amino acid sequence of
Fig. 2. By using the same protocol, we also obtained a mutant BV TK gene
lacking 30 bp (856 to 885); see the deleted sequence in Fig. 2.
Expression and purification of recombinant BV TK from bacterial cells. Ex-
pression and purification of the BV TK were carried out as described by the
manufacturer of Ni-NTA Superflow resin (QIAGEN). Briefly, a fresh overnight
saturated culture of Escherichia coli (JM109 strain) transformed with the recom-
binant pHis-BV-TK was diluted 1:100 in 1 liter of 2XYT broth (10 g/liter
Bacto-yeast extract, 16 g/liter Bacto-tryptone, 5 g/liter NaCl; Gibco) containing
ampicillin (60 g/ml) and incubated at 37°C with shaking. At an optical density
at 600 nm of 0.6, IPTG was added to a final concentration of 1 mM, and the
culture was incubated for another 4 h at 37°C. After centrifugation, the bacterial
cell pellet was resuspended in 4 volumes of lysis buffer (50 mM sodium phos-
phate [pH 8.0], 300 mM NaCl, 10 mM imidazole, 1 mM phenylmethanesulfonyl
fluoride, and 1 mg/ml lysozyme) and incubated on ice for 30 min. Cells were then
sonicated on ice, and the lysate was centrifuged at 10,000  g for 30 min at 4°C.
The supernatant was loaded on a Ni-NTA Superflow column (1 ml), and at a flow
rate of 0.25 ml/min, the column was first washed with lysis buffer and then with
50 mM sodium phosphate buffer (pH 8.0) containing 300 mM NaCl and 20 mM
imidazole. The protein was step eluted with 250 mM imidazole in 50 mM sodium
phosphate buffer (pH 8.0), 300 mM NaCl, and 1 mg/ml bovine serum albumin.
Fractions were collected for enzymatic activity analysis. The TK enzyme, col-
lected from peak fractions, was dialyzed against 50 mM Tris-HCl (pH 7.5)
containing 20% glycerol and 1 mM dithiothreitol (DTT) and frozen in liquid
nitrogen until use. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
analysis (Fig. 3) showed a predominant protein band at 40 kDa of approximately
98% purity. We also expressed and purified the BV TK mutant lacking 30 bp (see
above). Once eluted from the Ni-NTA column, this enzyme was found com-
pletely inactive in our assay conditions. This finding rules out the possibility that
E. coli TK contaminates our wild-type BV TK preparation.
TK activity assay. Recombinant BV TK was assayed at 37°C for 20 min in 25
l of a reaction mixture containing 30 mM HEPES K, pH 7.5, 6 mM MgCl2, 6
mM ATP, 0.5 mM DTT, and 1 M of [methyl-3H]TdR (2,200 cpm/pmol). The
reaction was terminated by spotting 20 l of the reaction mixture on a 23-mm
DEAE paper disks (DE-81; Whatman). The disks were washed twice in an excess
of 1 mM ammonium formate (pH 5.6) in order to remove unconverted nucleo-
side and washed once in ethanol. Filters were dried, and radioactivity was
counted in 1 ml of Betamax (ICN) scintillation fluid. One unit is defined as the
amount of enzyme that phosphorylates 1 nmol of TdR to TMP in 1 hour at 37°C.
Enzyme activity was linear up to 40 min. For inhibitor assays, stock solutions of
FIG. 1. Structures of nucleosides and related compounds referred to in this work.
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inhibitors in dimethyl sulfoxide (DMSO) were serially diluted into enzyme assay
mixtures. The enzyme was assayed with at least five inhibitor concentrations in
duplicate to determine the inhibitor concentration reducing activity by 50%
(IC50) in the above assay. When inhibitor Kis were measured, the assay was
carried out at several concentrations of [3H]TdR.
TK substrate assay. When nucleoside analogs were tested as possible sub-
strates of BV TK, each compound (100 M) was incubated at 37°C for 0, 10, 20,
30, and 40 min in a mixture (25 l) containing 30 mM HEPES K, pH 7.5, 6 mM
MgCl2, 6 mM ATP, 0.5 mM DTT, and the required amount of enzyme. Samples
were then heated at 100°C for 5 min and centrifuged for 15 min at 10,000 rpm in
an Eppendorf bench centrifuge. Supernatants were transferred to a new tube for
subsequent high-performance liquid chromatography (HPLC) analysis. The re-
verse-phase chromatography method used to separate nucleosides from nucle-
otides employed a Shimadzu HPLC system, consisting of an ALLTIMA C18-
NUC 100A 5U column (4.6 mm  25 cm) (Alltech) at room temperature under
the following conditions: injection volume, 20 l; detection, UV 260 nm; eluents
of the linear gradient, buffer A (20 mM KH2PO4, pH 7.5) and buffer B (20 mM
KH2PO4, pH 5.2, 60% methanol); elution time, 40 min from 0% to 100% buffer
B; and flow rate, 0.5 ml/min. Two independent experiments were performed in
which each point was run in duplicate. Enzyme activity was linear up to 40 min.
Percentage values were calculated by analysis of the UV peak areas eluted from
the column by using the Shimadzu class VP chromatography data system 4.3.
Antiviral assays. Virus stocks were diluted in cold DMEM containing 2%
FBS, and six-well trays containing confluent monolayers of Vero cells were
infected with 200 l/well of virus (to yield 150 to 200 PFU/well). Drugs were
dissolved in DMSO at 10 mg/ml and diluted in overlay medium (DMEM con-
taining 2% FBS and 0.25% methylcellulose). After 1 h of adsorption at 37°C, the
viral inoculum was removed, and cells were overlaid with 2.5 ml of medium. Each
drug concentration was tested in duplicate wells. Plates were incubated at 37°C
for 36 to 48 h, and plaques were counted. The percent plaque reduction was
calculated based on the number of plaques obtained in the absence of drugs.
Cytotoxicity assays. Drugs were dissolved in DMSO and threefold serially
diluted (200 to 0.1 g/ml) in growth medium, DMEM supplemented with 10%
fetal calf serum, containing 2.5 Ci/ml of [methyl-3H]TdR (25 Ci/mmol; Amer-
sham). Each drug was assayed in three independent experiments. The 15%
confluent Vero cells were incubated in 5% CO2/95% air at 37°C for 2 days, and
cells were collected with an automated cell harvester onto fiberglass filters.
Trichloroacetic acid (10%) was added to digest the cells, and trichloroacetic
acid-precipitable counts were determined in a scintillation counter. Mean control
incorporation into DNA was 3,720  331 cpm.
RESULTS
Recombinant BV thymidine kinase. The DNA sequence of
the BV TK gene from the standard laboratory strain E2490 has
been published (14). Because E2490 is an attenuated vaccine
strain of BV, it was necessary to determine whether the E2490
TK was representative of nonattenuated field isolates of BV.
We therefore sequenced the TK gene of two field isolates of
BV, one from a rhesus macaque (strain 12930; GenBank ac-
cession number EF426677) and one from a cynomolgous
FIG. 2. Alignment of BV and HSV-1 TK sequences. Amino acids constituting the ATP and the nucleoside binding sites are indicated, and all
residues that are conserved between HSV-1 and all BV isolates are highlighted in gray. Residues that differ between the cynomolgous and rhesus
BV sequences are indicated by black triangles under the sequences. The 10 amino acids (residues 270 to 279) deleted in the mutant recombinant
BV TK referred to in the text are indicated by a black bar under the sequences.
FIG. 3. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
of the affinity-purified recombinant BV TK. Lanes: M, molecular mass
markers; BV-TK, 6 g of recombinant TK eluted from the Ni-NTA
column (98% pure by densitometry [see Materials and Methods]).
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macaque (strain E90-136; GenBank accession number
EF426678). The TK genes were amplified by PCR, and the
PCR products were purified and sequenced without cloning.
The amino acid sequences (Fig. 2) of the rhesus BV isolates
E2490 and 12930 were identical, and the cynomolgous E90-136
BV sequence differed by only 14 amino acids (3.6%), 11 of
which were conservative substitutions. Amino acid sequence
homology between the BV and HSV TKs was considerably less
(approximately 55% identical and 65% similar). However,
amino acid residues of the HSV TK that have been identified
as part of the ATP and nucleoside binding sites or otherwise
critical to TK activity were all conserved in the BV TK
polypeptide (Fig. 2).
Kinetic properties of recombinant BV TK. In order to de-
termine the Km and Vmax of BV TK, we assayed a limiting
amount of enzyme with several concentrations of [3H]TdR and
the reaction velocity V was determined at each substrate con-
centration. Figure 4 shows the kinetics of TdR phosphorylation
by recombinant BV TK. Analysis revealed that the enzyme had
Km and Vmax values for TdR of 0.7 M and 0.2 nmol/h/g,
respectively (see also Table 3). The Km value of 1 M for
recombinant HSV-1 TK was similar (13), but the specific
activity of the HSV-1 enzyme was higher (17 nmol/h/g; F.
Focher, unpublished results) than the value for BV TK.
Inhibition of BV TK by nucleosides and related compounds.
We first tested several nucleoside analogs for their ability to
inhibit the phosphorylation of [3H]TdR catalyzed by BV TK,
and Table 1 shows the IC50 values of the compounds tested.
Certain analogs of TdR, e.g., 5-trifluoromethyl (TFT), 5-iodo
(IUdR), and 5-ethyl (Et-dU) derivatives, were potent inhibi-
tors, but the E-5-bromovinyl derivative, BVdU, was a weak
inhibitor. The latter result contrasts with the reported high
affinity of BVdU for HSV-1 TK, a Ki of 0.24 M (2). The
acyclonucleoside antiherpes drugs ACV and GCV weakly in-
hibited BV TK activity; IC50 values of ca. 1 mM could only be
estimated at the highest concentrations of ACV and GCV
tested (Table 1). The weak inhibition by ACV and GCV seems
unexpected, but in fact these acycloguanosines do not have
high affinity even for the HSV TK enzymes (9). For example,
the IC50 values for ACV against recombinant HSV-1 and
HSV-2 TKs were 122 and 200 M, respectively (F. Focher,
unpublished observations). In contrast, the “methylene” iso-
steres of ACV and GCV, viz., HBG and PCV, respectively,
were at least 10-fold more active as inhibitors of BV TK than
the acyclonucleosides themselves (Table 1).
The HSV TK inhibitors HBPG and several 2-phenylgua-
nines were moderately potent as inhibitors of BV TK but ca.
10-fold weaker than their activity against HSV TKs (13). Mis-
cellaneous nucleoside analogs, e.g., arabinosyladenine (araA),
lyxofuranosyluracil, and 6-methyluridine, and the  anomer of
Et-dU, did not inhibit BV TK at 100 M (not shown).
FIG. 4. Kinetics of BV TK activity in the presence of increasing
concentrations of [3H]TdR. Under the assay conditions described in
Materials and Methods, enzyme velocity of 2,200 cpm/20 min corre-
sponds to 0.2 nmol of TdR transformed to TMP in 1 h by 1 g of
enzyme.
TABLE 1. Effects of nucleoside analogs on BV TK activity (IC50)
a
Nucleoside analog Acronym IC50 (M) (mean  SD)b
Thymidine analogs
5-Trifluoromethyl-2-deoxyuridine TFT 2.0  0.1
L-Thymidine L-TdR 4.1  0.02
E-5-(Bromovinyl)deoxyuridine BVdU 32.3  3.5
L-5-(Bromovinyl)deoxyuridine L-BVdU 15.0  2.0
5-Iododeoxyuridine IUdR 1.5  0.2
L-5-Iodo-2-deoxyuridine L-IUdR 2.0  0.2
5-Ethyl-2-deoxyuridine Et-dU 0.15  0.01
-5-Ethyl-2-deoxyuridine -Et-dU 52  5.0
5-Propyl-2-deoxyuridine Pr-dU 4.2  0.2
Acyclonucleosides
Acyclovir ACV 1,000  210
Ganciclovir GCV 800  112
Cidofovir CFV 900  155
Penciclovir PCV 84.4  5.5
2-Amino-9-(4-hydroxybutyl)-6-oxopurine HBG 177  20
HSV TK inhibitors
N2-(3-Trifluoromethylphenyl)guanine CF3PG 3.5  0.15
2-Phenylamino-9-(4-hydroxy-butyl)-6-oxopurine HBPG 11.5  1.0
2-Phenylamino-9-(N,N-dimethylaminobutyl)-6-oxopurine DMBPG 1.2  0.15
a Enzyme assays contained 1 M [3H]TdR and were run in duplicate with at least five concentrations of inhibitor.
b The values are the means for two independent experiments in which each concentration was tested in duplicate.
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Substrate properties of nucleosides and analogs. The re-
combinant BV TK enzyme was also used to evaluate whether
it was able to phosphorylate various nucleoside derivatives and
acyclonucleosides (Table 2), which could then be considered
possible antiviral drugs. The possible substrates ACV, GCV,
CFV, PCV, TFT, IUdR, BVdU, and HBPG were incubated at
both 0.1 and 1 mM with excess BV TK. Reaction mixtures were
analyzed by reverse-phase HPLC, and UV peak areas of start-
ing compound and putative phosphorylated product were used
to determine the kinetics of phosphorylation, if any. Under
assay conditions which resulted in the complete phosphoryla-
tion of TdR to its monophosphate TMP, the compounds TFT,
PCV, IUdR, BVdU, and HBPG were phosphorylated with
different efficiencies (Fig. 5), but ACV, GCV, and CFV were
very poorly or not phosphorylated under these conditions (data
not shown). Interestingly, the HSV TK inhibitor HBPG was
very efficiently phosphorylated with a Km of 7.4 M and a Vmax
of 3.9 nmol/h/g. Table 3 shows the kinetic properties of
HBPG compared with those of the natural substrate TdR.
Comparison of Vmax/Km ratios, which estimate the efficiency of
phosphorylation, indicate that BV TK phosphorylated HBPG
with an efficiency 1.8 times greater than for TdR.
BV TK is not enantioselective. When BV TK was incubated
with L-TdR under conditions that resulted in the formation of
the 5-monophosphate of the natural substrate D-TdR, the
phosphorylation rate was similar to that of the natural sub-
strate. BV TK displayed Km and Vmax values of 0.65 M and
0.15 nmol/h/g, respectively, for L-TdR (Table 3). The lack of
enantioselectivity of BV TK was also confirmed by similar
inhibition by the D and L enantiomers of BVdU and IUdR
(Table 1).
Antiviral activity in Vero cell cultures. Plaque reduction
assays were conducted in Vero cells infected with several
strains of BV and, for comparison, with HSV-1. Strains of BV
included 24105 and E90-136, both neuropathogenic in mice,
and 32425, a strain that is nonpathogenic in mice, and the F
strain of HSV-1. Duplicate cell cultures were infected with 150
to 200 PFU of virus for 1 h and then overlaid with medium
containing various concentrations of the drug (or vehicle). The
plaque morphology of BV varied with the drug concentration,
making the quantitation of drug sensitivity difficult to assess.
With increasing drug concentrations, the first effect noted was
a decrease in plaque size. At higher drug concentrations, the
characteristic syncytial activity of BV was inhibited, resulting in
small clumps of rounded cells. For the purpose of these stud-
ies, foci of viral cytopathic effect were counted as plaques only
if there was an area of clearing (cell lysis); the size of the
plaque was not considered. Percent reduction of virus plaque
formation was determined after 36 to 48 h of incubation at
37°C. For comparison, cytotoxicity in uninfected Vero cells was
TABLE 2. Phosphorylation of nucleoside analogs





L-TdR ...................................................................................130  8.0
TFT....................................................................................... 55  4.2
BVdU ................................................................................... 0
L-BVdU................................................................................ 0
IUdR .................................................................................... 58  2.5
L-IUdR ................................................................................. 94  4.3
Et-dU.................................................................................... 82  4.1




PCV ...................................................................................... 72  5.1
HBPG...................................................................................200  25
HBG ..................................................................................... 94  7.2
a Determined by HPLC analysis of reaction mixtures containing BV TK after
30 min of incubation.
b Relative to the mean of TdR, 0.5 nmol TMP produced in the assay reaction
conditions (see Materials and Methods). Zero values indicate no detectable
monophosphate at 100 M or 1 mM.
FIG. 5. Kinetics of phosphorylation of nucleoside analogs by BV
TK. Panel A shows 100 M TdR (F), HBPG (E), IUdR (), BVdU
(f), and Et-dU (‚). Panel B shows 1 mM TdR (F), PCV (E), HBG
(f), and Pr-dU (). Each nucleoside analog was incubated for the
indicated time in the assay mixture described in Materials and Meth-
ods, and the products of the reaction were resolved by HPLC as
described in Materials and Methods (100% corresponds to 2.5 nmol of
substrate converted to monophosphate).
TABLE 3. Kinetic properties of phosphorylation of substrates
by BV TKa
Substrate Km (M)(mean  SD)b
Vmax (nmol h1 g1)
(mean  SD)b Vmax/Km
TdR 0.70  0.05 0.20  0.005 0.28
HBPG 7.40  0.047 3.90  0.1 0.52
L-TdR 0.65  0.15 0.15  0.008 0.23
a Assayed at variable concentrations of substrate.
b The values are the means from two independent experiments in which each
concentration was tested in duplicate.
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determined by measuring [3H]TdR incorporation by the DNA
of proliferating cells. Approximate values of antiviral 50% ef-
fective concentration (EC50) and cytotoxic concentration of
drug that reduced cellular DNA synthesis by 50% (CC50) of
tested compounds are listed in Table 4.
Anti-BV potency generally followed the ability of the com-
pounds to be substrates for BV TK. The most potent com-
pound was TFT, with EC50 values of 1.7 and 3.4 M against
two BV strains, nearly as potent as its activity against HSV-1.
The other TdR analogs were also active, with the exception of
BVdU. The estimated EC50 values of BVdU of 	330 M
contrasts with its potent activity against HSV-1 (EC50 of 0.12
M; see also reference 6). IUdR and Et-dU were active, al-
though somewhat weaker than their activity against HSV-1.
The acyclonucleosides ACV and GCV were about 10-fold
weaker against BV than against HSV-1, as previously reported
(1, 3). Their weaker activity is consistent with, although not
completely explained by, their lack of observed substrate sen-
sitivity toward BV TK (Table 3). PCV, the methylene isostere
of GCV (see structures in Fig. 1), was only three- to fourfold
weaker against the BV strains than against HSV-1 (Table 4),
an observation consistent with the efficient phosphorylation of
PCV by BV TK (Table 3). PCV was reported to have an affinity
to HSV-1 TK similar to that of TdR, although it was phosphor-
ylated at only 9% of the rate for TdR at 250 M (11). Does this
simple change in structure give rise to this difference in prop-
erties of O-containing and CH2-containing 9-substituted gua-
nines? A similar parallel at the level of TK was observed
between HBG, the methylene isostere of ACV, and ACV it-
self. HBG, a compound with weak anti-HSV activity and a
weak substrate for HSV-1 TK (10), was an efficient substrate
for BV TK (Table 3).
Other anti-HSV drugs tested—CFV, PFA, and araA—had
similar activity against the BV strains and HSV-1. The TK
inhibitor/substrate HBPG was inactive against both viruses.
Cytotoxicity was noted with thymidine analogs that are ex-
pected to be phosphorylated by the host TK (TFT and IUdR)
and by araA (Table 4). Other TdR analogs and acyclonuceo-
sides had little cytotoxic effect between 600 and 1,000 M
(Table 4), including the close substrate relative Et-dU.
DISCUSSION
We have expressed and assayed the BV thymidine kinase
and have established a BV-infected cell culture system. Al-
though the BV and HSV TKs show similar Km values for the
natural substrate, screening of various antiherpes drugs, exper-
imental compounds, and TK inhibitors/substrates has revealed
different responses of the BV and HSV enzymes (Tables 1 and
2). Most notably, the acyclonucleosides ACV and GCV that
are the mainstay of anti-HSV drugs bind weakly to and are not
detectably phosphorylated (“activated”) by BV TK under the
conditions used. However, the methylene isostere of GCV, i.e.,
PCV, is a reasonable substrate. Thymidine analogs, such as the
anti-HSV drug IUdR and 5-alkyldeoxyuridines, are well phos-
phorylated, but surprisingly, the potent anti-HSV drug BVdU
is not. N2-Phenylguanines act as inhibitors of BV TK but are
less potent than against HSV TKs. The lead anti-HSV TK
compound HBPG inhibited and was readily phosphorylated by
BV TK. The L enantiomers of nucleosides were phosphory-
lated at rates similar to those of their D counterparts, showing
a lack of stereoselectivity of BV TK similar to that reported for
the HSV enzymes (8, 12, 16, 17).
Results of anti-BV testing generally paralleled the results of
BV TK testing (Table 4). The thymidine analogs IUdR, TFT,
and Et-dU were especially potent anti-BV compounds, al-
though the first two compounds were also cytotoxic. Nucleo-
side analogs that were not phosphorylated had weaker activity
(ACV and GCV) or lacked anti-BV activity (BVdU) compared
to their potency against HSV-1. One exception was the phos-
phonate CFV, which was a moderately potent antiviral, prob-
ably because it bypasses the phosphorylation step. PFA and
HBPG were weak anti-BV compounds, weaker even than their
activity against HSV.
The most potent anti-BV compounds iododeoxyuridine
(IUdR) and TFT are not suitable development candidates for
TABLE 4. Plaque reduction in BV-infected and HSV1-infected Vero cells and cytotoxicity in uninfected Vero cells by nucleoside analogs
Nucleoside
analog
Antiviral EC50 (M)a (mean  SD) Cytotoxicity (CC50e [M]
[mean  SD])BV 24105 BV 32425 BV E90-136 HSV-1 F
ACV 112  65b 118  71c 47.5  24b 1.4  0.13d 	890
GCV 14.5  12c 23.5  23.9d 19.2  13.7c 0.7  0.23d 666  106
PCV 17.0  8.7b 25.3  13.8d 17.3  11.4c 4.7  2.1d 	790
IUdR 11.2 8.5 NT 2.8 6.8  2.5
TFT 1.7 3.4 NT 
1.7 50.6  9.8
BVdU 		300 		300 NT 0.12 	600
Et-dU 37.4  20.3c 48.0  26c 13.3  14.8b 2.1  0.8d 	780
CFV 28.9 21.6 NT 14.4 	720
PFA 	500 ca. 250 NT 250 	1,000
araA 28 35 NT 7 38  7.72
HBPG 	330 	330 NT 330 	660
a From single plaque reduction experiments (n  1) run in duplicate, unless indicated otherwise. NT, not tested.
b n  5.
c n  4.
d n  3.
e CC50, cytotoxic concentration of drug that reduced the viable cell number by 50%. Data were from [3H] TdR incorporation studies of subconfluent Vero cells in
triplicate.
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BV infections. IUdR and TFT have been used topically for
HSV keratitis but are too toxic for systemic use because they
are nonselectively phosphorylated by viral and host cell TKs
and have significant cytotoxicity (Table 4). araA is both a
potent antiviral and cytotoxic compound. CFV, although also a
potent antiviral drug with a broad spectrum of activity, has
limitations; it is available only as an intravenous formulation
and can be nephrotoxic if multiple administrations are needed
for therapeutic use.
The most promising anti-BV compounds that we have iden-
tified are Et-dU and PCV. Et-dU is equal to or more potent
than the currently recommended drug ACV, and its potency is
comparable to the potency of GCV (Table 4). Et-dU has been
marketed in the past (in Europe and Canada) as a topical
treatment for ocular herpes infections. A summary of its clin-
ical pharmacology suggests that it is a relatively nontoxic but
highly efficacious antiherpes drug (4, 7). Its high water solubil-
ity may make it a prime candidate for testing against BV
encephalitis, and it may also warrant a second look as treat-
ment for HSV encephalitis. PCV is currently marketed as a
topical drug, although its diacetylated, 6-deoxy prodrug form
famciclovir is available for systemic use.
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